ICH E6(R3) and E8(R1) are often discussed separately but in practice, they reinforce each other.
Together, they shift clinical research from checklist execution to purposeful design and proactive oversight.
Where E8(R1) focuses on how to design meaningful and patient-relevant studies, E6(R3) focuses on how to conduct those studies with transparency, quality, and documented oversight.
Trials are more complex, timelines are tighter, and patient populations are more specific.
Both guidelines push organizations to:
This results in fewer surprises, smoother execution, and clearer inspection narratives.
You don’t “choose” E6(R3) or E8(R1). You use E8(R1) to design the study and use E6(R3) to run it responsibly.
Organizations that align study design (E8) with operational oversight (E6) create trials that are:
If you are using the MyRBQM® Portal, CtQ factors, risk reviews, and monitoring decisions can be linked directly to study documentation — supporting inspection-ready traceability.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
Industry Solutions
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
